HSCSP-COVIRNA

TOCOVID

Primary Purpose: the samples to be used within COVIRNA were collected as part of the clinical study registered with the "ClinicalTrials.gov Identifier: NCT04332094". Randomized Interventional Pilot Phase II Clinical Trial; SARS-CoV-2 infection; Primary outcomes: mechanical ventilation, In-hospital mortality.
Study Types: TOCOVID
Description of Cohorts: This consisted on hospitalized adults (men and women =>18 years of age at the time of inclusion in the study), who can provide written informed consent before beginning any study procedure. Confirmation of SARS-CoV-2 infection by a microbiological test performed before randomization, no longer than 72 hours. Patients were no included when presenting: comorbidities that imply a poor prognosis; pregnancy or breast-feeding; serious or active bacterial infections by pathogens other than SARS-CoV-2; immunosuppressive treatment; previous evidence of latent untreated tuberculosis.
Informed Consent Given?: True
Multi-center Study?: True